The escalating battle between Pfizer and activist investor Starboard Value has taken a dramatic twist, with allegations that Pfizer’s former CEO Ian Read and former CFO Frank D’Amelio were coerced into flipping sides. In a recent public letter to Pfizer’s board, Starboard accused the company of threatening to claw back compensation and cancel unvested stock unless the former executives publicly supported current CEO Albert Bourla. These claims introduce a new layer of complexity to Starboard’s campaign to overhaul Pfizer’s leadership and strategic direction.
https://lnkd.in/e3brXTVY
Starboard's $1 billion stake in Pfizer, first reported earlier this week, came amid growing dissatisfaction with the drugmaker's performance. Shares of Pfizer ($PFE) have plummeted by over 50% since their pandemic-era peak, a concerning development given the company’s attempts at cost-cutting, M&A-driven pipeline expansions, and executive reshuffles. Starboard's efforts, initially bolstered by support from Read and D’Amelio, were seen as a potential turning point for a company struggling to regain favor with investors.
https://lnkd.in/eKzCVCR6
However, the abrupt reversal by Read and D’Amelio, now distancing themselves from Starboard's plans, signals a messy internal conflict that could destabilize Pfizer further. The possibility of litigation, clawbacks, and threats from Pfizer’s leadership adds to the tension and could alienate shareholders who are already wary of the company's trajectory. Starboard has called for an independent investigation into the allegations, which, if proven true, could further erode confidence in Pfizer's governance and leadership.
This public debacle, unfolding ahead of a high-stakes meeting with Bourla, Starboard, and key Pfizer board members, underscores the immense pressure on Pfizer to justify its recent strategies. While the company has focused heavily on rebuilding its pipeline post-COVID, with key moves in oncology and cost-cutting measures, Starboard's aggressive intervention suggests that these efforts may not be enough to satisfy investors who are eager for a faster and more significant turnaround.
As Pfizer faces mounting scrutiny, particularly with a contentious board meeting on October 16th looming, the unfolding events could have lasting implications for both its governance and long-term strategy. The company's leadership must now not only address Starboard's concerns but also navigate the public controversy surrounding Read and D’Amelio's retraction of support. With both financial performance and boardroom drama at play, the situation presents a critical juncture in determining the future course of one of the world’s largest pharmaceutical companies.
#Pfizer #CEO #CFO #BoardofDirectors #HedgeFund #Starboard
CEO | ex-VC | Drug developer | Strategic advisor | Board member
5moFantastic match!